>

>

Demand modeling and scenario planning for a novel, mass-market agent for hypercholesterolemia

Service Areas
Therapeutic Areas

Other Therapeutic Areas

Client Type

Mid-size Pharma

Client Problems

  • A small but highly-valued biopharma client sought to quantify the opportunity for a new hypercholesterolemia product across 6 patient segments and 3 physician specialties


  • More specifically, they wanted to know which product attributes will drive share uptake vs. the market-leading statins and the classes in late-stage development (PCSK9i and CETPi)

What We Did

  • Given the landscape, a methodology was needed to process a large amount of feedback efficiently


  • We conducted a quantitative conjoint study with n=300 physicians across 3 specialties; as well as 20 qualitative payer interviews


  • Using this primary data, we created an annual revenue forecast capable of flexible scenario planning

Our Results And Insight

  • Understand baseline patient segmentation


  • The benefit of LDL lowering was shown to vary by drug class (statins vs. non-statins) – a critical, new insight


  • Respondents were segmented by unmet needs in the cholesterol market (e.g. LDL-C, risk reduction and compatibility with statins)


  • Drivers analysis for differences between upside and downside revealed insights for commercial resource allocation

See other case studies

Market Research case studies >

Other Therapeutic Areas case studies >

Service Areas Details

Market Research (Demand Modelling, Scenario Planning)

Therapeutic Areas Details

Other Therapeutic Areas (Cardiovascular)

© 2019, First Principles Advisory Group. All Rights Reserved
SF Bay Area, Denver, Seattle, New York City, Cambridge
First Principles Advisory Group
1290 Howard Street Suite 323
Burlingame, CA 94010
(415) 669-5183
info@fpadvisory.net